Company Overview - Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][3] - The company is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, and is also assessing its combination with a GLP-1R agonist (Wegovy®) [3] Industry Insights - The South by Southwest (SXSW) conference serves as a global platform for thought leaders and industry experts to discuss emerging trends in health and medtech, particularly in the context of weight loss medicine [2] - The panel session titled "Weighing in on Weight Loss Medicine" will explore the future of obesity management beyond GLP-1 drugs, indicating a shift towards innovative solutions in the obesity treatment landscape [2][1]
Skye Bioscience to Participate in SXSW Session on Obesity